Technology Behind GlycoGenesys' Oncology Drug Candidate Subject of Journal of National Cancer Institute Publication
Wednesday January 8, 8:32 am ET
Study Reports Patented Pectin Derived Compound Inhibits Cancer Tumor Growth and Metastasis In Mouse Models
BOSTON--(BUSINESS WIRE)--Jan. 8, 2003-- GlycoGenesys, Inc. (NASDAQ:GLGS - News) today announced that researchers from the Barbara Ann Karmanos Cancer Institute released a study in the current edition of the Journal of National Cancer Institute Volume 94, Issue 24 involving technology which the Barbara Ann Karmanos Cancer Institute and Wayne State University have exclusively licensed their worldwide rights to GlycoGenesys, Inc. The article by Drs. Raz, Nangia-Makker and colleagues, entitled "Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin," describes a study comparing mice injected with human breast or colon cancer cells and fed modified citrus pectin to a control group that were not. The study found that both the breast and colon human cancer tumor growth, tumor blood vessel formation (angiogenesis), and metastasis were significantly inhibited in the mice receiving modified citrus pectin as compared to the control group.
The Company's human therapeutic candidate for the treatment of multiple indications of cancer GCS-100 is a formulation of modified citrus pectin being developed currently for IV administration. GCS-100 has been evaluated in Phase II(a) clinical trials for both colorectal and pancreatic cancer. In February 2002, the Company initiated a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California.
GlycoGenesys, Inc.
GlycoGenesys is a biopharmaceutical company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. In February 2002, the Company initiated a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California. In the area of agriculture, GlycoGenesys continues to seek strategic alternatives for Elexa-4® Plant Defense Booster. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
The j/v is no more, although Elan has retained an interest in the company. Apart from that the take-home message seems to be: "Eat more lemons, or else".
Erik |
